Pediatric liver transplantation outcomes from a single center in Thailand

doi:10.4254/wjh.v14.i3.583

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5036)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

303

WORD

HTML

1990

Figures (1-3)

261

Tables (1-2)

269

Sum=2915

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

219

Download

394

Sum=613

Publishing Process of This Article

Item

Count

Browse

428

Download

1080

Sum=1508

Mar 27, 2022 (publication date) through Jan 13, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Hepatol. Mar 27, 2022; 14(3): 583-591
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.583

Table 2 Donor and recipient laboratory findings

Data set		Living donors (n = 77)	Deceased donors (n = 17)	Total (n = 94)
ABO incompatibility¹	n, %	8 (10.4)	0 (0)	8 (8.5)
Positive donor anti-HBc	n, %	4 (5.2)	4 (23.5)	8 (8.5)
Anti-CMV IgG (n, %)²	D+/R-	8 (11.0)	2 (18.2)	10 (11.9)
	D+/R+	62 (84.9)	9 (81.8)	71 (84.5)
	D-/R+	3 (4.1)	0 (0)	3 (3.6)
	D-/R-	0 (0)	0 (0)	0 (0)
Recipient positive serology (n/total, %)	HBsAg	0/44 (0)	0/9 (0)	0/53 (0)
	Anti-HBs	33/43 (76.7)	3/10 (30)	36/53 (67.9)
	Anti-HBc	3/44 (6.8)	2/10 (20)	5/54 (9.3)
	Anti-HCV	1/42 (2.4)	0/10 (0)	1/52 (1.9)
	Anti-EBV IgG	31/43 (72.1)	8/9 (88.9)	39/52 (75)

¹Median age at liver transplantation (IQR) = 0.9 (0.5-1.0) years.

²Total 84 patients.

D: Donor; R: Recipient; HBsAg: Hepatitis B surface antigen; Anti-HBs: Hepatitis B surface antibody; Anti-HBc: Hepatitis B core antibodies; Anti-HCV: Hepatitis C virus antibodies; Anti-EBV: Epstein-Barr virus antibodies.

Citation: Prachuapthunyachart S, Sintusek P, Tubjareon C, Chaijitraruch N, Sanpavat A, Phewplung T, Wanawongsawad P, Intrarakamhang AL, Chongsrisawat V. Pediatric liver transplantation outcomes from a single center in Thailand. World J Hepatol 2022; 14(3): 583-591
URL: https://www.wjgnet.com/1948-5182/full/v14/i3/583.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i3.583